

Form 39A [See Rule 150E(f)] Under the Drugs and Cosmetics Act 1940 and the Rules thereunder

Sample Name #	FLUCONAZOLE TABLETS IP 150 mg	Report No.	[REDACTED]
		Mfg. Lic. No.#	
Mfd. By#	N/A	Date of Receipt	16/09/2024
Supplied By#	N/A		Sample Qty.#
Submitted By Address	MEGHALAYAN MEDICAL DRUGS AND SERVICES NEW COLONY SHILLONG, DHS LAITUMKHAH, OFFICE OF THE MANAGING DIRECTOR MMSDSL EAST	Batch Size#	NA
		Mfg.Date#	07/2024
		Exp.Date#	06/2026
Ref. No.#	N/A	Batch No.#	MMSDSL/QC/-0479

NS

Date of Start of Analysis : 16/09/2024

Date of Completion of Analysis : 19/09/2024

RESULTS OF ANALYSIS

Reference to Protocol : IP 2022

DESCRIPTION

: White round shape biconvex uncoated tablet scored on one side and other side plain.

S.No.	PARAMETERS/TEST	RESULTS	LIMIT	
1	IDENTIFICATION (BY HPLC)	Complies		
2	AVERAGE WEIGHT	233.21 mg		
3	UNIFORMITY OF WEIGHT	Within Limit	± 7.5%	
4	DISSOLUTION	Avg 94.36% (Min. 91.35 Max. 96.87%)	Q NLT 80%	
5	RELATED SUBSTANCES (BY HPLC)			
	AREA OF ANY SECONDARY PEAK	Not detected	NMT 1.0%	
	SUM OF ALL THE SECONDARY PEAK	Not detected	NMT 2.0%	
6	ASSAY (BY HPLC)	Each uncoated tablet contains.		
	COMPOSITION	RESULTS	LABEL CLAIM	LIMITS
	FLUCONAZOLE IP	142.13 mg	150 mg	135mg to 165mg
				PROTOCOL
				IP-2022

Remarks : In the opinion of the undersigned, the sample referred above is of standard quality as defined in the Drugs Act 1940 and Rules made their under for the reasons given below as per IP 2022
Sample Consume in testing

*****END OF REPORT*****

Represents Customer Defined Fields

Date of Issue : 13/11/2024

Note:-

1. Sample (s) not drawn by us unless otherwise stated.
2. Total liability of our analytical division is limited to the invoiced amount.
3. Sample will be destroyed after one month from the date of issue of test certificate unless otherwise specified.
4. Test certificate in full or parts shall not be use for promotional or publicity purpose.
5. Result given in report in related to sample tested only.